Literature DB >> 27693615

Variegated RHOA mutations in human cancers.

Keisuke Kataoka1, Seishi Ogawa2.   

Abstract

RHOA is one of the most extensively investigated members of the Rho GTPase family of proteins and has long been implicated in malignant transformation as well as tumor invasion and metastasis. Recently, revolutionized sequencing platforms have revealed frequent RHOA mutations in a wide variety of human cancers, including angio-immunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, germinal center B-cell lymphoma, diffuse-type gastric cancer, and other solid tumors. With their discrete positional distributions and types of amino acid substitution depending on cancer type, different RHOA mutations seem to have unique functional and biological properties. However, their impact on the development of different types of tumors remains controversial. Here, we present an overview of the current understanding of RHOA mutations in human cancers and highlight the unanticipated complexity of their genetic and biological properties.
Copyright © 2016 ISEH - International Society for Experimental Hematology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27693615     DOI: 10.1016/j.exphem.2016.09.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Quantitation of RhoA activation: differential binding to downstream effectors.

Authors:  Yu-Wen Zhang; Holly M Torsilieri; James E Casanova
Journal:  Small GTPases       Date:  2022-01

2.  The to and fro of Rho.

Authors:  Kenneth D Westover
Journal:  Structure       Date:  2021-06-03       Impact factor: 5.006

3.  Structure of an inactive conformation of GTP-bound RhoA GTPase.

Authors:  Yuan Lin; Shaoyong Lu; Jian Zhang; Yi Zheng
Journal:  Structure       Date:  2021-01-25       Impact factor: 5.871

Review 4.  Genetic alterations in adult T-cell leukemia/lymphoma.

Authors:  Yasunori Kogure; Keisuke Kataoka
Journal:  Cancer Sci       Date:  2017-07-29       Impact factor: 6.716

5.  Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.

Authors:  Izuma Nakayama; Eiji Shinozaki; Seiji Sakata; Noriko Yamamoto; Junko Fujisaki; Yusuke Muramatsu; Toru Hirota; Kengo Takeuchi; Shunji Takahashi; Kensei Yamaguchi; Tetsuo Noda
Journal:  Cancer Sci       Date:  2019-04       Impact factor: 6.716

6.  The diagnostic and prognostic role of RhoA in hepatocellular carcinoma.

Authors:  Yi Bai; Fucun Xie; Fei Miao; Junyu Long; Shan Huang; Hanchun Huang; Jianzhen Lin; Dongxu Wang; Xu Yang; Jin Bian; Jinzhu Mao; Xi Wang; Yilei Mao; Xinting Sang; Haitao Zhao
Journal:  Aging (Albany NY)       Date:  2019-07-22       Impact factor: 5.682

7.  Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.

Authors:  Yangying Zhou; Zhijie Xu; Wei Lin; Yumei Duan; Can Lu; Wei Liu; Weiping Su; Yuanliang Yan; Huan Liu; Li Liu; Meizuo Zhong; Jianhua Zhou; Hong Zhu
Journal:  Front Oncol       Date:  2019-07-25       Impact factor: 6.244

8.  Case Report: Immune Microenvironment and Mutation Features in a Patient With Epstein-Barr Virus Positive Large B-Cell Lymphoma Secondary to Angioimmunoblastic T-Cell Lymphoma.

Authors:  Fen Zhang; Wenyu Li; Qian Cui; Yu Chen; Yanhui Liu
Journal:  Front Genet       Date:  2022-07-22       Impact factor: 4.772

Review 9.  Targeting cytoskeletal phosphorylation in cancer.

Authors:  Clara Llorente-González; Marta González-Rodríguez; Miguel Vicente-Manzanares
Journal:  Explor Target Antitumor Ther       Date:  2021-06-28

Review 10.  Claudins and Gastric Cancer: An Overview.

Authors:  Itaru Hashimoto; Takashi Oshima
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.